PolarCool AB (publ) presents results with statistical significance from concussion study with PolarCap® System
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System.
The clinical pilot study with PolarCap® System as treatment method for concussion in ice hockey, has now been analyzed in collaboration with the Department of Mathematics at Umeå University and the company's scientific advisors, Professor Emeritus Yelverton Tegner and Professor Niklas Marklund.
In total, 52 cases have been reported so far in the study, and the results, which are statistically significant, show that players treated with PolarCap® return to play 33% earlier than players who have not received treatment.
- These interesting results will culminate in a scientific publication from Lund University. We will also present the results for the elite ice hockey organizations in the upcoming period, announces CEO Iman Ziai.
The study has been conducted during three seasons, in collaboration with the Swedish Hockey League (SHL) and HockeyAllsvenskan, wherein PolarCap® System has been evaluated for the treatment of concussion.
A total of 12 teams have participated in the study; The intervention group has used PolarCap® System and the control group has consisted of players who have not received the treatment.
The purpose of the clinical study has been to measure symptom relief, in order to examine how quickly the player progresses through a mandatory rehab program until return to play. The program is a rehabilitation process with progressively increased activity that lasts for at least 6 days, where the last step involves full participation in training or match (so-called Return To Play).
The median time for return to play for the intervention group, treated with PolarCap® System, was 7 days and for those not treated 10.5 days. The results are statistically significant (p = 0.038).
In addition, more players in the control group (3 out of 16; 19%) were absent from games longer than 3 weeks, compared to the intervention group (2 out of 25; 8%). However, this data is small, and the results cannot therefore be statistically confirmed.
Overall, the results show that early cooling as an acute treatment method for concussions in this study has had positive effects.
This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on April 8, 2019.
For more information
Iman Ziai – VD
+46 - 733 -99 23 17
E-mail: iman.ziai@polarcool.se
About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.